Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Feb 01, 2005 (Vol. 25, No. 3)

ParAlign and Smith-Waterman

URL:www.paralign.org/
  • Fast sequence snalysis
  • Sparse pickings
ParAlign and Smith-Waterman, hosted by the Center for Molecular Biology and Neuroscience (CMBN) at Rikshospitalet University Hospital in Oslo, Norway, provides the ParAlign sequence analysis tool. A note on the opening page indicates the analysis engine is powered by a 66 CPU cluster. Users can search amino acid and/or nucleotide sequences and a wide variety of databases are available. The site is a bit sparse in details. The About page claims they have the fastest implementation of Smith-Waterman searching available anywhere and that the process is patent pending. Besides this, there is little other general information available at the site, which is unfortunate, because I was left wondering more about the analyses provided.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »